Corona, DanielaEkser, BurcinGioco, RossellaCaruso, MassimoSchipa, ChiaraVeroux, PierfrancescoGiaquinta, AlessiaGranata, AntonioVeroux, Massimiliano2021-02-012021-02-012020-05-30Corona, D., Ekser, B., Gioco, R., Caruso, M., Schipa, C., Veroux, P., Giaquinta, A., Granata, A., & Veroux, M. (2020). Heme-Oxygenase and Kidney Transplantation: A Potential for Target Therapy? Biomolecules, 10(6), 840. https://doi.org/10.3390/biom10060840https://hdl.handle.net/1805/25104Kidney transplantation is a well-established therapy for patients with end-stage renal disease. While a significant improvement of short-term results has been achieved in the short-term, similar results were not reported in the long-term. Heme-oxygenase (HO) is the rate-limiting enzyme in heme catabolism, converting heme to iron, carbon monoxide, and biliverdin. Heme-oxygenase overexpression may be observed in all phases of transplant processes, including brain death, recipient management, and acute and chronic rejection. HO induction has been proved to provide a significant reduction of inflammatory response and a reduction of ischemia and reperfusion injury in organ transplantation, as well as providing a reduction of incidence of acute rejection. In this review, we will summarize data on HO and kidney transplantation, suggesting possible clinical applications in the near future to improve the long-term outcomes.en-USAttribution 4.0 Internationalkidney transplantationdeceased donorliving donorheme-oxygenaseend-stage renal diseaseorgan transplantationischemia-reperfusion injurybrain deathArticle